Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shanchol is a brand of inactivated (killed) whole-cell oral cholera vaccine indicated for active immunization against *Vibrio cholerae* serogroups O1 and O139. It is administered orally and does not require a buffer solution. The vaccine induces local immunity in the gastrointestinal tract by exposing the immune system to killed *V. cholerae* cells, leading to protection against infection. Two doses given at least two weeks apart provide protection for up to 3–5 years in individuals over one year of age; a single dose offers short-term protection. Shanchol is primarily used for mass vaccination campaigns in endemic areas or during outbreaks and humanitarian crises[1][2][4][5]. The primary developer and manufacturer is Sanofi Healthcare India Private Limited[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cholera vaccine (inactivated, oral).